Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission

Marina Díaz-Beyá; Myriam Labopin; Johan Maertens; Mahmoud Aljurf; Jakob Passweg; Beelen Dietrich; Harry Schouten; Gerard Socié; Nicolaas Schaap; Rainer Schwerdtfeger; Liisa Volin; Mauricette Michallet; Emmanuelle Polge; Jorge Sierra; Mohamad Mohty; Jordi Esteve; Arnon Nagler; Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

doi:10.1111/bjh.16433

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission

Br J Haematol. 2020 Jun;189(5):920-925. doi: 10.1111/bjh.16433. Epub 2020 Feb 5.

Authors

Marina Díaz-Beyá^{1

2}, Myriam Labopin³, Johan Maertens⁴, Mahmoud Aljurf⁵, Jakob Passweg⁶, Beelen Dietrich⁷, Harry Schouten⁸, Gerard Socié⁹, Nicolaas Schaap¹⁰, Rainer Schwerdtfeger¹¹, Liisa Volin¹², Mauricette Michallet¹³, Emmanuelle Polge³, Jorge Sierra¹⁴, Mohamad Mohty^{3

15}, Jordi Esteve^{1

2

16}, Arnon Nagler^{3

17}; Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Affiliations

¹ Hematology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
² IDIBAPS, Josep Carreras Leukemia Research Institute, Barcelona, Spain.
³ EBMT Paris Study Office, Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Paris, France.
⁴ University Hospital Gasthuisberg, Leuven, Belgium.
⁵ King Faisal Specialist Hospital & Research Centre Oncology, Riyadh, Saudi Arabia.
⁶ University Hospital Hematology, Basel, Switzerland.
⁷ Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.
⁸ Department of Internal Medicine, Hematology/Oncology, University Hospital, Maastricht, The Netherlands.
⁹ Division of Hematology, Hospital Saint Louis & University Paris, Paris, France.
¹⁰ Radbud University Medical Centre, Nijmegen, The Netherlands.
¹¹ Center for Hematopoietic Cell Transplantation, Deutsche Klinik für Diagnostik Helios Klinik, Wiesbaden, Germany.
¹² Stem Cell Transplantation Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
¹³ Hôpital Edouard Herriot, Lyon, France.
¹⁴ Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Santpau and Josep Carreras Leukemia Research Institute, Autonomous University of Barcelona, Barcelona, Spain.
¹⁵ Department of Hematology, Hospital Saint Antoine, Paris, France.
¹⁶ Medicine Department, University of Barcelona, Barcelona, Spain.
¹⁷ Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

PMID: 32020596
DOI: 10.1111/bjh.16433

Abstract

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0·001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.

Keywords: AML; DEK-NUP214; allo-SCT; prognosis; t(6;9) AML.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Allografts
Chromosomal Proteins, Non-Histone / genetics*
Chromosomes, Human, Pair 6 / genetics*
Chromosomes, Human, Pair 6 / ultrastructure
Chromosomes, Human, Pair 9 / genetics*
Chromosomes, Human, Pair 9 / ultrastructure
Cord Blood Stem Cell Transplantation*
Disease-Free Survival
Female
Gene Duplication
Graft vs Host Disease / etiology
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Nuclear Pore Complex Proteins / genetics*
Oncogene Proteins / genetics*
Oncogene Proteins, Fusion / genetics*
Peripheral Blood Stem Cell Transplantation*
Poly-ADP-Ribose Binding Proteins / genetics*
Proportional Hazards Models
Remission Induction
Translocation, Genetic*
Treatment Outcome
fms-Like Tyrosine Kinase 3 / genetics

Substances

Chromosomal Proteins, Non-Histone
DEK protein, human
NUP214 protein, human
Nuclear Pore Complex Proteins
Oncogene Proteins
Oncogene Proteins, Fusion
Poly-ADP-Ribose Binding Proteins
FLT3 protein, human
fms-Like Tyrosine Kinase 3

Abstract

Publication types

MeSH terms

Substances

Grants and funding